e-learning
resources
Vienna 2012
Tuesday, 04.09.2012
MDR- and XDR-TB: clinical and public health experiences
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Long term treatment outcome in multi drug resistant tuberculosis
R. Prasad, A. Singh, S. Verma, R.S. Kushwaha, R. Garg, S.K. Verma, R. Srivastava, A. Jain (Etawah, Lucknow, Kanpur, India)
Source:
Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Session:
MDR- and XDR-TB: clinical and public health experiences
Session type:
Poster Discussion
Number:
3324
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Prasad, A. Singh, S. Verma, R.S. Kushwaha, R. Garg, S.K. Verma, R. Srivastava, A. Jain (Etawah, Lucknow, Kanpur, India). Long term treatment outcome in multi drug resistant tuberculosis. Eur Respir J 2012; 40: Suppl. 56, 3324
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Long term treatment out come in multi drug resistant tuberculosis
Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis
Year: 2010
Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011
Predicting outcomes and drug resistance with standardised treatment of active tuberculosis
Source: Eur Respir J 2010; 36: 870-877
Year: 2010
Long-term results of drug resistant tuberculosis treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 378s
Year: 2006
Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis
Source: Eur Respir J , 49 (3) 1601799; DOI: 10.1183/13993003.01799-2016
Year: 2017
Treatment outcome of multi-drug resistant tuberculosis
Source: Annual Congress 2004 - Problems of resistance and HIV coinfection in tuberculosis
Year: 2004
Our experience in multi drug resistant tuberculosis (MDR TB) treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 652s
Year: 2005
Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis
Source: Eur Respir J, 50 (5) 1701552; 10.1183/13993003.01552-2017
Year: 2017
Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB
Source: Eur Respir J 2009; 33: 1085-1094
Year: 2009
Is standardized treatment appropriate for non-XDR multiple drug resistant TB?
Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis
Year: 2008
The efficacy of treatment of patients with drug resistant tuberculosis
Source: Eur Respir J 2007; 30: Suppl. 51, 661s
Year: 2007
Predictors of treatment outcome in multidrug-resistant tuberculosis
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011
Treatment outcome of multidrug resistant tuberculosis with second line drugs
Source: Eur Respir J 2001; 18: Suppl. 33, 314s
Year: 2001
Drug resistant tuberculosis at a drug resistant tuberculosis centre, India- Analysis of outcome
Source: International Congress 2017 – TB: co-morbidities and outcome
Year: 2017
Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB)
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis?
Source: Eur Respir J 2009; 34: 1492-1494
Year: 2009
The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Patient choice promotes adherence in preventive treatment for latent tuberculosis
Source: Eur Respir J 2007; 30: 728-735
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept